# abcarta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abcarta

- Industry: Healthcare
- Headquarters: Suzhou, China
- Website: www.abcarta.com
- Latest round: Series A (Nov 25, 2019)
- Investors on record: 4

## About

Founded in 2018 and based in Suzhou, China, abcarta operates as a medical company that focuses on the research and development of intelligent pathology solutions. It was recognized as the National High-tech Enterprise. The company has R&D and production centers, as well as medical information and artificial intelligence centers in Suzhou and San Diego, the United States. In November 2019, abcarta closed a series A funding from new investors Juncheng Capital, Tahoe VC, and Xinyuyan Biotechnology Service (Suzhou).

The company mainly provides intelligent pathology solutions for pathologists, scientific research institutions, and new drug development partners. Products include PathAb antibodies, 100-channel kits, FAIP-30 automatic immunohistochemistry staining instrument, remote pathology diagnosis platform, etc.

The company generates revenue by providing intelligent pathology products and services.

## Funding rounds

- Series A, Nov 25, 2019 — Tahoe VC, Xinyuyan Biotechnology Service (Suzhou), Juncheng Capital
- Angel, Dec 10, 2018 — Bohe Angel Fund

## Investors

- Bohe Angel Fund — Angel
- Tahoe VC — Series A
- Xinyuyan Biotechnology Service (Suzhou) — Series A
- Juncheng Capital (https://capitalatlas.ai/funds/juncheng-capital) — Series A